光生物调节治疗干性年龄相关性黄斑变性12个月多中心随机对照试验结果
这项为期12个月的多中心随机双盲对照试验纳入78例早期或中期干性年龄相关性黄斑变性患者的138只眼,评估光生物调节(PBM)的解剖与功能疗效。结果显示PBM组平均玻璃膜疣体积(MDV)显著下降而假治疗组上升,最佳矫正视力(BCVA)组间差异为+3.75个字母(95%CI 1.16至6.34;p=0.0001),且未观察到视网膜光毒性。
要点
- PBM组12个月MDV下降(-0.03±0.05 mm³),假治疗组上升(+0.02±0.04 mm³),p<0.001。
- PBM组BCVA改善(+1.31±6.7个字母),假治疗组下降(-2.62±7.1个字母),组间差异+3.75个字母(95%CI 1.16至6.34;p=0.0001)。
- 假治疗组4只眼发生黄斑新生血管,PBM组无(p=0.044);未观察到视网膜光毒性。
核心结论
- PBM在12个月内显著降低早期和中期dAMD的玻璃膜疣负荷并改善视功能,安全性良好。
- 研究结果支持PBM作为非新生血管性年龄相关性黄斑变性的有前景治疗选择,但需更长随访确认其延缓疾病自然进程的作用。
研究设计与样本
- 为期12个月的多中心、随机、双盲、假治疗对照临床试验。
- 纳入78例早期或中期dAMD患者的138只眼。
- 主要结局为基线至12个月平均玻璃膜疣体积(MDV)变化,次要结局包括最佳矫正视力(BCVA)变化和不良事件。
- 采用多水平混合效应回归分析治疗-时间交互作用。
主要发现
- 12个月时PBM组MDV显著下降(-0.03±0.05 mm³),假治疗组上升(+0.02±0.04 mm³),p<0.001。
- PBM组BCVA改善(+1.31±6.7个字母),假治疗组下降(-2.62±7.1个字母),组间差异+3.75个字母(95%CI 1.16至6.34;p=0.0001)。
- 女性性别和较高AREDS分类与MDV随时间增加相关(p=0.030和p=0.003),较高年龄与MDV降低相关(p=0.049)。
- 假治疗组4只眼发生黄斑新生血管,PBM组无(p=0.044);PBM组1只眼发生地图样萎缩(p=1.00)。
- 未观察到视网膜光毒性病例。
临床怎么用
- 对于早期和中期干性AMD患者,PBM可能作为降低玻璃膜疣负荷和改善视功能的治疗选项。
- 治疗前应评估AREDS分类和性别等与MDV增加相关的因素。
- 需关注假治疗组中黄斑新生血管的发生,PBM组未出现视网膜光毒性。
局限性
- 需要更长随访的研究来确认PBM在潜在延缓疾病自然进程中的作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Dry age-related macular degeneration (dAMD) is the leading cause of irreversible vision loss in older adults, with no approved treatment to modify progression in early and intermediate stages. Photobiomodulation (PBM), which targets mitochondrial dysfunction and retinal inflammation, has shown promise in early studies. This study aims to evaluate the anatomical and functional efficacy of PBM in eyes with early and intermediate dAMD. METHODS: In this 12-month, multicentre, randomised double-masked controlled trial, 138 eyes from 78 patients with early or intermediate dAMD were included. The primary outcome was change in mean drusen volume (MDV) from baseline to 12 months. Secondary outcomes included change in best-corrected visual acuity (BCVA) and adverse events. Multilevel mixed-effects regression was used to analyse treatment-time interactions. RESULTS: MDV decreased significantly in the PBM group (-0.03±0.05 mm³) while increased in the sham group (+0.02 ± 0.04 mm³; p<0.001) at 12 months. The PBM group also showed a significant improvement in BCVA (+1.31 ± 6.7 letters) compared with a decline in the sham group (-2.62±7.1 letters), yielding a between-group difference of +3.75 letters (95% CI 1.16 to 6.34; p=0.0001). Female sex and higher Age-Related Eye Disease Study (AREDS) category were associated with MDV increase over time (p=0.030 and p=0.003; respectively), while older age was associated with MDV reduction (p=0.049). Four eyes in the sham group developed macular neovascularisation, compared with none in the PBM group (p=0.044), while one eye in the PBM group developed geographic atrophy (p=1.00). No cases of retinal phototoxicity were observed. CONCLUSION: PBM significantly reduced drusen burden and improved visual function in early and intermediate dAMD over 12 months, with an excellent safety profile. These findings support PBM as a promising therapeutic option for patients with non-neovascular age-related macular degeneration, despite further studies with longer follow-up are needed to confirm the role of PBM in potentially slowing the natural course of the disease.
引用
- Iovino C, Borrelli E, Coco G, et al. 12-month outcomes of photobiomodulation in dry age-related macular degeneration: a prospective multicentre randomised double-masked controlled clinical trial. Br J Ophthalmol. 2026. PMID: 42259594. doi:10.1136/bjo-2025-328389
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。